Serotonin 2C Receptor Agonists and Type 2 Diabetes
Author Information
Author(s): Zhou Ligang, Sutton Gregory M., Rochford Justin J., Semple Robert K., Lam Daniel D., Oksanen Laura J., Thornton-Jones Zoe D., Clifton Peter G., Yueh Chen-Yu, Evans Mark L., McCrimmon Rory J., Elmquist Joel K., Butler Andrew A., Heisler Lora K.
Primary Institution: Department of Clinical Biochemistry, Addenbrooke's Hospital, University of Cambridge
Hypothesis
Do serotonin 2C receptor agonists improve glucose tolerance in murine models of obesity and type 2 diabetes?
Conclusion
Serotonin 2C receptor agonists significantly improve glucose tolerance and reduce plasma insulin in murine models of obesity and type 2 diabetes through melanocortin-4 receptor signaling pathways.
Supporting Evidence
- 5-HT2CR agonists improved glucose tolerance in diet-induced obese mice.
- Treatment with mCPP reduced fasting plasma insulin by 49%.
- The effects of 5-HT2CR agonists were independent of changes in food intake and body weight.
Takeaway
This study found that a type of medicine that affects serotonin can help mice with diabetes manage their blood sugar better without making them lose weight.
Methodology
Mice were treated with serotonin 2C receptor agonists and their glucose tolerance and insulin levels were measured.
Limitations
The study was conducted on murine models, which may not fully replicate human physiology.
Participant Demographics
Male ob/ob mice and DIO mice were used in the study.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website